The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobial resistance (AMR). Building upon its initial US$25 million grant in 2024, the Novo Nordisk Foundation is now increasing its contribution with US$60 million in funding over the next four years.
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives.
Bacterial infections are the second leading cause of death worldwide. The rise of AMR, which makes many bacterial infections increasingly difficult to treat, further compounds this critical global health challenge.
AMR is associated with 4.7 million deaths worldwide every year and is projected to take 39 million lives between 2025 and 2050 – an average of three deaths every minute. AMR disproportionately affects people living in low- and middle-income countries and threatens decades of progress in modern medicine by increasing the risks associated with routine surgeries, cancer treatment, childbirth, and many essential medical procedures.
There is an urgent need for new antibiotics, diagnostics, vaccines, and other preventive tools – but a lack of investment and limited commercial incentives over the last decades have left the global innovation pipeline too thin. Established in 2016 to help fill that gap, CARB-X is now the world’s leading non-profit public-private partnership accelerating innovation against bacterial infections and AMR.
Addressing antimicrobial resistance requires ambition, expertise and sustained collaboration across sectors and borders.CARB-X brings these strengths together in a proven model that helps promising innovations advance further and faster. Supporting the development of new tools to prevent, diagnose, and treat drug-resistant infections is a key priority for the Novo Nordisk Foundation, and expanding our commitment to CARB-X is therefore a natural next step.
Marianne Holm, Vice President, Infectious Diseases at the Novo Nordisk Foundation.
Supported by a coalition of governments, foundations, and global health organizations, CARB-X pairs grant funding with comprehensive technical and scientific support, resulting in supported projects being five times more likely to advance into clinical development than comparable projects that did not receive CARB-X support. Since 2016, CARB-X has supported more than 120 research and development projects in 15 countries, and CARB-X-supported product developers have made significant progress: 29 projects have already advanced into or completed clinical trials.
Developing innovative products to prevent, diagnose, and treat drug-resistant infections is essential both to protect patients and to strengthen health systems worldwide. Gram-negative bacteria including Escherichia coli (E. coli), Salmonella, and Klebsiella pneumoniae are particularly difficult to treat once they develop resistance. The regular release of new, potent antibiotics targeting these bacteria – which are one of CARB-X’s strategic priorities – could save an estimated 11.1 million lives from 2025 to 2050. These new products would also reduce health care costs by US$84 billion, generate improved health outcomes worth US$174 billion, and add US$740 billion to global GDP per year by 2050.
New preventatives such as vaccines and diagnostic tools would also positively impact global health, helping to curb antibiotic overuse and misuse through the prevention of infections before they occur and the detection of bacterial infections and resistance at the point of care, therefore guiding appropriate and timely treatment.
The Novo Nordisk Foundation’s renewed partnership is a powerful endorsement of the impact that collaboration can achieve in strengthening the global response to antimicrobial resistance. This support will help us continue identifying and advancing the most promising innovations from anywhere in the world while building a stronger and more sustainable pipeline of products that can save lives globally.
Kevin Outterson, Executive Director of CARB-X
The Novo Nordisk Foundation’s renewal strengthens the coalition of organizations partnering with CARB-X to address bacterial infections and AMR through sustained investment in innovation and early planning for global stewardship and access. Together, CARB-X and its partners are helping ensure that groundbreaking science can progress from discovery through clinical development and ultimately reach patients who urgently need new solutions.






